Caterina Buquicchio
A5063611419- COVID-19 and healthcare impacts
- COVID-19 Clinical Research Studies
- Acute Myeloid Leukemia Research
- SARS-CoV-2 and COVID-19 Research
- Neutropenia and Cancer Infections
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Respiratory viral infections research
- Hematological disorders and diagnostics
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- Fungal Infections and Studies
- COVID-19 Impact on Reproduction
- Virus-based gene therapy research
- Retinoids in leukemia and cellular processes
- Complement system in diseases
- Lymphoma Diagnosis and Treatment
- Long-Term Effects of COVID-19
- Antifungal resistance and susceptibility
- Cancer Treatment and Pharmacology
- Dermatological and COVID-19 studies
- Cutaneous lymphoproliferative disorders research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Genetic and Kidney Cyst Diseases
PHI University Psychiatric Clinic - Skopje
2023
Istituti di Ricovero e Cura a Carattere Scientifico
2022
University Hospital Cologne
2022
University of Cologne
2022
Heinrich Heine University Düsseldorf
2022
Düsseldorf University Hospital
2022
University of Bari Aldo Moro
2003-2005
Palmetto Hematology Oncology
2001
Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics HM patients developing COVID-19 and analyzed predictors mortality. The survey was supported by the Scientific Working Group Infection Hematology European Association (EHA). Eligible analysis were adult laboratory-confirmed...
Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and between January 2021 March 2022 were analyzed. A total 1548 cases included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing 753 (49%), the Omicron variant was prevalent (517, 68.7%). Most received ≤2 vaccine doses before (1419, 91%), mostly...
Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management AML patients COVID-19 has not been established. Our multicenter study included 388 adult diagnosed between February 2020 and October 2021. vast majority were receiving or had received treatment in the preceding 3 months. was severe 41.2% critical 21.1% cases. chemotherapeutic schedule modified 174 (44.8%), delayed 68 permanently discontinued 106. After a...
BackgroundThe COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, monoclonal antibodies have been effective the general population, their benefits these patients may not be as pronounced.MethodsThe EPICOVIDEHA registry (National Clinical Trials Identifier, NCT04733729) gathers data from malignancy since pandemic's...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes life-threatening COVID-19 in hematologic malignancy (HM) patients, associated with high morbidity and mortality this particularly vulnerable population.1 After more than years since the beginning of pandemic, several prophylactic therapeutic strategies have been developed against SARS-CoV-2, including targeted antivirals, monoclonal antibodies vaccines, leading to improved prognosis HM patients.2 Our preliminary data...
<title>Abstract</title> A real-life study on CPX-351 and the standard arm (‘7 + 3’) of registrative trial in adults with secondary Acute Myeloid Leukemia were compared by an unanchored Matching-adjusted indirect comparison (MAIC), order to evaluate efficacy toxicity CPX-351. Results this are important confirm role significantly improving survival remission rates ‘7 3’ a good safety profile AML patients high-risk features, target group traditionally very poor prognosis. Moreover, pilot...
Elderly patients with hematologic malignancies face the highest risk of severe COVID-19 outcomes. The infection's impact on different age groups remains unstudied in detail.We analyzed elderly (age groups: 65-70, 71-75, 76-80, and >80 years old) included EPICOVIDEHA registry between January 2020 July 2022. Univariable multivariable Cox regression models were conducted to identify factors influencing death hematological malignancy.The study data from 3,603 (aged 65 or older) malignancy, a...
Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression severe SARS-CoV-2 infections decrease hospitalisation mortality rates. Nirmatrelvir/ritonavir was authorised in Europe December 2021, whereas molnupiravir is not yet licensed as of February 2022. may be an alternative because it associated with fewer drug-drug interactions contraindications. A caveat for the mode action induces viral mutations. Mortality rate reduction less pronounced than that patients...
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent (20)19 disease (COVID-19)-related death. The changing epidemiological therapeutic scenarios suggest that there has been improvement in severity survival COVID-19 during the different waves pandemic general population, but this not investigated yet MM patients. Here we analyzed a large cohort 1221 patients with confirmed SARS-CoV-2...
Since the beginning of COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates hospitalization, intensive care unit (ICU) admissions, and In comparison other patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large database (EPICOVIDEHA), demonstrated that majority CML...
The potential drug-drug interactions of midostaurin may impact the choice antifungal (AF) prophylaxis in FLT3-positive acute myeloid leukemia (AML) patients. To evaluate incidence invasive fungal diseases (IFD) during treatment FLT3-mutated AML patients and to correlate it different AF strategies, we planned a multicenter observational study involving 15 SEIFEM centers. One hundred fourteen treated with chemotherapy + as induction/reinduction, consolidation or both were enrolled. During...
Patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPN) typically incur high rates of infections and both drugs comorbidities may modulate infection risk.The present study aims to assess the effect immunosuppressive agents on clinical outcomes MPN patients affected by coronavirus disease 2019 (COVID-19).This is an observational study.We specifically searched analyzed collected EPICOVIDEHA online registry, which includes individuals hematological malignancies diagnosed...
To evaluate clinical impact of ceftazidime/avibactam on treating infections due to MDR Gram-negative bacteria in patients with haematological malignancies (HMs). We conducted a retrospective, observational study at 17 Italian wards that included HMs receiving for the treatment suspected or proven infections. The primary endpoint was all-cause mortality 30 days after infection onset. Secondary endpoints development vitro resistance, adverse reactions and relapse. Of 198 enrolled, 66 had fever...
The Philadelphia (Ph) chromosome is the cytogenetic hallmark of chronic myeloid leukemia (CML) and observed in more than 90% CML cases. At diagnosis, 5-10% patients Ph derived from variant translocations other standard t(9;22). Deletions adjacent to translocation junction on derivative 9 were recently described by different groups. deletions may identify a subgroup with worse prognosis. presence similar third 22 chromosomes has never been investigated. We studied three cases variants showing...
Background: The outcome of patients with simultaneous diagnosis haematological malignancies (HM) and COVID-19 is unknown there are no specific treatment guidelines. Methods: We describe the clinical features a cohort 450 HM registered in EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia lymphoma were most frequent (35.8% 35.1%, respectively). Overall, 343 (76.2%) received for HM, which was delayed longer than one month since 57 (16.6%). An overall response...